CUE BIOPHARMA INC (CUE) Stock Price & Overview
NASDAQ:CUE • US22978P1066
Current stock price
The current stock price of CUE is 0.1799 USD. Today CUE is down by -11.2%. In the past month the price decreased by -37.49%. In the past year, price decreased by -73.35%.
CUE Key Statistics
- Market Cap
- 14.165M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.31
- Dividend Yield
- N/A
CUE Stock Performance
CUE Stock Chart
CUE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CUE. When comparing the yearly performance of all stocks, CUE is a bad performer in the overall market: 96.77% of all stocks are doing better.
CUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CUE. CUE has a bad profitability rating. Also its financial health evaluation is rather negative.
CUE Earnings
CUE Forecast & Estimates
5 analysts have analysed CUE and the average price target is 4.08 USD. This implies a price increase of 2167.93% is expected in the next year compared to the current price of 0.1799.
For the next year, analysts expect an EPS growth of -17.07% and a revenue growth -87.5% for CUE
CUE Groups
Sector & Classification
CUE Financial Highlights
Over the last trailing twelve months CUE reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 58.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.02% | ||
| ROE | -100.64% | ||
| Debt/Equity | 0.03 |
CUE Ownership
CUE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CUE
Company Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Company Info
IPO: 2018-01-02
CUE BIOPHARMA INC
40 Guest Street
Boston MASSACHUSETTS 02139 US
CEO: Daniel R. Passeri
Employees: 41
Phone: 16179492680
CUE BIOPHARMA INC / CUE FAQ
What does CUE do?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Can you provide the latest stock price for CUE BIOPHARMA INC?
The current stock price of CUE is 0.1799 USD. The price decreased by -11.2% in the last trading session.
Does CUE BIOPHARMA INC pay dividends?
CUE does not pay a dividend.
How is the ChartMill rating for CUE BIOPHARMA INC?
CUE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CUE stock?
5 analysts have analysed CUE and the average price target is 4.08 USD. This implies a price increase of 2167.93% is expected in the next year compared to the current price of 0.1799.
What is the GICS sector and industry of CUE stock?
CUE BIOPHARMA INC (CUE) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of CUE BIOPHARMA INC (CUE) based on its PE ratio?
CUE BIOPHARMA INC (CUE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).